DCAL Q4 FY25 earnings call filed, guides 20% margin and INR 750 cr EBITDA in 2-3 years

Management guided margin improvementOrder pipeline disclosedMulti-year targets disclosedCFO laid out a debt-reduction roadmapInvestor Communications View source PDF Explain this filing

DCAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.7%Reaction day

₹268.55

prior close

₹268.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-1.1% vs market

Pharmaceuticals peers, median of 147sector+0.5%-1.2% vs sector

On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-1.0

15m

-0.4

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.7+0.4-1.1+0.5-1.2

Next day

-0.7+0.7-1.4-0.2-0.5

+0.8+0.7+0.0-0.3+1.1

+0.7+0.5+0.2-0.5+1.2

-0.8+1.0-1.8-0.1-0.7

+1.8+1.5+0.3-0.1+1.9

+2.3+2.8-0.5+0.4+1.9

15d

-10.7-0.7-10.0-2.8-8.0

-6.9+3.7-10.6+0.2-7.1

-5.7+3.0-8.7+1.4-7.1

-1.2-1.4+0.2-4.2+3.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dishman Carbogen Amcis filed Q4 and FY25 earnings call transcript. Revenue grew 3.7% to INR 2,711 cr. EBITDA surged to INR 472 cr (margin 17.4%) from INR 296 cr. Q4 EBITDA margin hit 21.4%. FY26 EBITDA is guided around INR 550-570 cr with margin closer to 20%. Management targets INR 750 cr EBITDA in 2-3 years and 12-15% revenue CAGR over 3-5 years. Net debt of INR 157 mn (CHF) guided to fall INR 100-200 cr yearly. French facility fully operational with revenue set to double in FY26.

Likely market impact

Strong margin expansion guidance and debt reduction roadmap signal earnings recovery. Watch French entity turnaround and India CRAMS scaling to INR 800 cr peak.